New diabetes drug imeglimin takes on metformin in mitochondrial showdown
NCT ID NCT07436182
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares two diabetes medications—imeglimin and metformin—in 176 adults newly diagnosed with type 2 diabetes. Participants will take one of the two drugs for 12 weeks. The main goal is to see which drug better improves mitochondrial function, measured by a blood test called the pyruvate/lactate ratio. Researchers will also check blood sugar control and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Imeglimin and metformin
What this could lead to
If imeglimin works better than metformin at improving mitochondrial function, it could offer a new first-line treatment option for type 2 diabetes.
What could go wrong
This is a small, early-phase trial (176 people) that hasn't started yet. It measures a biomarker (pyruvate/lactate ratio) rather than long-term outcomes, so success here may not translate to better diabetes control or fewer complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METFORMIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mansoura university hospitals
Al Mansurah, Province, 31951, Egypt